This article refers to 'Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes' by M. Palazzini et al., published in this issue on pages 248-255.
In particular, the role of the DPG in predicting survival in PH-LHD as shown by some groups 5 -7 is subject to controversy as the analyses of other cohorts have failed to show the prognostic value of this variable. 8 -11 In this issue of the Journal, Palazzini et al. add another piece to the puzzle. 12 They present a retrospective, single-centre analysis of 276 patients with LHD who underwent invasive haemodynamic assessment between 1997 and 2015, in whom post-capillary PH (mean PAP ≥25 mmHg; mean PAWP >15 mmHg) was diagnosed. According to current guidelines, 4 the authors defined a group of patients with Cpc-PH [DPG ≥7 mmHg, PVR >3 Wood units (WU)], a group with Ipc-PH (DPG <7 mmHg; PVR ≤3 WU), and an 'intermediate' group in which only one of the two variables was elevated. They then estimated survival rates in the three groups using the Kaplan-Meier method and log-rank test with the aim of elucidating the prognostic values of PVR and DPG alone and in combination, as well as those of other haemodynamic indices. They found that patients with Ipc-PH had better survival than both patients with Cpc-PH (P = 0.026) and those in the intermediate group (P = 0.025). Furthermore, although patients with normal PVR had better survival compared with those with elevated PVR (P = 0.013), there were no differences in survival according to the level of DPG (P = 0.254) or level of transpulmonary pressure gradient (TPG; defined as the difference between mean PAP and PAWP) (P = 0.147). The authors also showed that, in addition to PVR, pulmonary arterial compliance (PAC), calculated as stroke volume divided by pulse pressure (difference between systolic and diastolic PAP), was also predictive of survival. In fact, a low PAC turned out to be the strongest predictor of death when analysed as a continuous variable (P = 0.001).
12

Illusion of conclusion?
These data must be interpreted in relation to the findings of a number of other studies that have assessed the prognostic values of haemodynamic variables in PH-LHD and unfortunately yielded +, predictive of survival; −, not predictive of survival; DPG, diastolic pressure gradient; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HTx, heart transplant; ND, not determined; PAC, pulmonary artery compliance; PVR, pulmonary vascular resistance; TPG, transpulmonary pressure gradient; VHD, valvular heart disease.
quite heterogeneous results 5 -14 ( Table 1 ). The distinct and in part contradictory findings may be explained by differences in methodology, definitions and threshold levels, 2,3 lack of standardization for optimized LHD treatment and volume load, as well as the fact that some studies investigated PH caused by LHD in general, whereas others focused on specific LHDs [i.e. heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), valvular disease] at various stages.
5 -14 Moreover, the potential bias induced by the retrospective nature of most studies must be acknowledged. Despite these limitations, we may conclude that the overall amount and quality of available data are insufficient to support any judgements on the prognostic value of haemodynamic variables in PH-LHD.
Nevertheless, the fog may be lifting as we collect more data, and the work by Palazzini et al. 12 adds important information. Firstly, it shows that a substantial number of patients with LHD and PH display an elevated PVR, which may or may not be associated with an increased DPG, whereas an isolated elevation of the DPG with normal PVR appears to be very rare, which is consistent with the findings of other groups. 15 Secondly, the subgrouping of post-capillary PH into Ipc-PH and Cpc-PH predicted survival in patients with PH-LHD, which is also in line with the results of several other studies.
5 -7,9-14 Thirdly, the 'intermediate' group was mainly driven by elevated PVR with normal DPG, and outcomes in this group did not differ from those in the group with Cpc-PH (i.e. elevated levels of PVR and DPG). Fourthly, pressure gradients (i.e. DPG, TPG) appeared to be of minor importance, whereas variables incorporating cardiac function (i.e. PVR, PAC) were superior in predicting outcome in PH-LHD, which is consistent with the majority of recent studies. 8 
-11
The main limitations of the study by Palazzini et al., 12 as well as of most other studies evaluating the role of pulmonary vascular indices for predicting survival in patients with LHD, 5 haemodynamics and right ventricular (RV)-pulmonary artery (PA) coupling are the same for various types and degrees of heart failure (HFpEF, HF with mid-range EF, HFrEF) and valvular disease (mitral stenosis/mitral regurgitation, aortic stenosis/aortic regurgitation), or other left heart conditions. However, this may not be the case. Hence, the available evidence remains limited and the existing data should be interpreted with caution. The heterogeneity of published data and the uncertainty about the diagnostic and/or prognostic value of single haemodynamic indices raise two key questions. Firstly, do we need a subclassification of PH-LHD and, if so, why? Given that the presence of PH and particularly a pre-capillary component of PH as well as impaired RV-PA coupling are associated with adverse outcomes, this question must be answered in the affirmative. However, future adjustments of the classification must be more precise about the diagnostic vs. the prognostic value of haemodynamic measures (which are certainly not the same), as improvement of our pathophysiological understanding and proper risk stratification in PH-LHD are warranted. Current work provides novel insights into the clinical, genetic and pathophysiological features of Ipc-PH vs. Cpc-PH.
11, 16 The key question concerns whether we can improve morbidity and mortality in selected patients with PH-LHD by targeting the pulmonary circulation and unloading the right ventricle. To this end, we have preliminary evidence at best.
17 -19 Secondly, based on pathophysiological considerations, which pulmonary vascular indices would be expected to indicate PVD and a higher likelihood of death?
The pathophysiological interplay between the left heart, pulmonary circulation and right heart is well established.
2 Indeed, several studies have shown that RV dysfunction is a strong and independent predictor of survival in patients with heart failure. 20 -22 Furthermore, impaired RV-PA coupling appears to be of particular importance to outcomes in HFpEF, 23 especially in patients with Cpc-PH. 24 It should be noted that RV workload is defined by pressures, rather than gradients, and that the adaptation of the right ventricle to an increased afterload is of key importance. 25 In that sense, RV afterload is composed of a steady (PVR) and a pulsatile (PAC) vascular load. Consistently, in several recent studies PVR and PAC outperformed the DPG in predicting mortality 10, 12, 13 and, hence, PVD in LHD may be best defined by measures incorporating RV function (i.e. PVR, PAC). 25 This claim, however, must be confirmed in larger trials. Furthermore, our current understanding and the classification of PH-LHD are based mainly on haemodynamics at rest, whereas impaired RV-PA coupling during moderate exercise is detected even in early stages of HFpEF, 26 and the increase in CO during exercise rather than CO at rest may be more relevant. 27 In this context, an abnormal pulmonary haemodynamic response during exercise is characterized by an excessive increase of PAP in relation to flow, and a currently proposed definition of 'exercise PH' is based on the relationship between Δmean PAP and ΔCO. 28 In summary, the current classification of PH-LHD needs to be refined and measures should be indicative of PVD, RV dysfunction and RV-PA coupling at rest and potentially during exercise, so that a combination of variables rather than a single parameter may be suitable for proper haemodynamic phenotyping.
In 2018, the Sixth World Symposium on Pulmonary Hypertension will be held in Nice, France; it will be a challenging goal to summarize current knowledge and adjust definitions in preparation for this. The current evidence is incomplete, preliminary in nature rather than definite, and partly contradictory. Hence, the belief that we are close to making conclusions may be illusory. As Palazzini et al. 12 point out, what we need are prospective, multicentre, adequately sized studies with pre-specified endpoints, inclusion criteria, subgroup definitions and uniform baseline assessments and follow-up strategies. Such studies should be based on our pathophysiological understanding and subclassification of PH-LHD, and conducted separately in patients with specific underlying LHDs. The final answers may come from therapeutic interventions, which may or may not be safe and efficacious in distinct subgroups of patients with PH attributable to LHD. Only then will we be ready to draw conclusions. Conflict of interest: none declared.
